Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MIST |
---|---|---|
09:32 ET | 353 | 1.46 |
09:34 ET | 100 | 1.49 |
09:36 ET | 459 | 1.4737 |
09:38 ET | 258 | 1.4601 |
09:39 ET | 100 | 1.4896 |
09:45 ET | 225 | 1.4789 |
09:48 ET | 100 | 1.47 |
09:50 ET | 100 | 1.475 |
09:52 ET | 1606 | 1.4735 |
09:56 ET | 340 | 1.46 |
10:03 ET | 3416 | 1.46 |
10:06 ET | 100 | 1.46 |
10:08 ET | 100 | 1.46 |
10:10 ET | 100 | 1.45 |
10:28 ET | 10522 | 1.47 |
10:30 ET | 100 | 1.47 |
10:32 ET | 200 | 1.47 |
10:33 ET | 200 | 1.465 |
10:35 ET | 100 | 1.46 |
10:42 ET | 200 | 1.46 |
10:44 ET | 500 | 1.464 |
10:46 ET | 1460 | 1.465 |
10:48 ET | 700 | 1.46 |
10:51 ET | 2232 | 1.4699 |
10:53 ET | 100 | 1.46 |
10:55 ET | 288 | 1.46 |
10:57 ET | 100 | 1.46 |
11:04 ET | 501 | 1.465 |
11:11 ET | 4329 | 1.45 |
11:13 ET | 536 | 1.45 |
11:20 ET | 100 | 1.455 |
11:26 ET | 4318 | 1.47 |
11:29 ET | 700 | 1.47 |
11:31 ET | 192 | 1.46 |
11:36 ET | 100 | 1.46 |
11:38 ET | 100 | 1.46 |
11:45 ET | 9608 | 1.43 |
11:47 ET | 100 | 1.44 |
11:54 ET | 500 | 1.44 |
11:56 ET | 1200 | 1.445 |
11:58 ET | 1100 | 1.442 |
12:03 ET | 301 | 1.455 |
12:05 ET | 100 | 1.442 |
12:16 ET | 1088 | 1.45 |
12:20 ET | 1100 | 1.45 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Milestone Pharmaceuticals Inc | 78.3M | -1.4x | --- |
Vistagen Therapeutics Inc | 81.2M | -2.0x | --- |
Chimerix Inc | 78.9M | -0.9x | --- |
IO Biotech Inc | 78.4M | -0.9x | --- |
ALX Oncology Holdings Inc | 79.0M | -0.4x | --- |
Aileron Therapeutics Inc | 77.3M | -1.1x | --- |
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $78.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.73 |
EPS | $-1.01 |
Book Value | $0.50 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.